Pre-Open Stock Movers 02/11: (ACIU) (MVIX) (DMTK) Higher; (FLDM) (ELY) (TLRY) Lower (more...)

Today's Pre-Open Stock Movers:

AC Immune SA (NASDAQ: ACIU) 88.5% HIGHER; announced positive interim results from its ongoing Phase 1b/2a clinical trial evaluating its first-in-class anti-phospho-Tau (pTau) vaccine candidate ACI-35.030 for the treatment of Alzheimers disease (AD). ACI-35.030 vaccination generated a potent antigen-specific antibody response against pTau in 100% of older patients with early AD, achieving antibody levels several orders of magnitude higher than pre-vaccination levels. No clinically relevant adverse events were observed. AC Immune and strategic partner Janssen Pharmaceuticals, Inc., believe these interim findings from the first two dosing groups support plans to advance the development of ACI-35.030 for the treatment of AD.

MicroVision, Inc. (NASDAQ: MVIS) 37.2% HIGHER; announced that it has received necessary components and equipment to meet its April milestone of completing A-Samples of its Long Range Lidar Sensor. The Company also announced that it has started outdoor testing of key performance features on its development platform.

DermTech, Inc. (NASDAQ: DMTK) 28.2% HIGHER; has contracted, effective 2/1/2021, with Blue Cross Blue Shield of Texas (“BCBSTX”) to make DermTech’s Pigmented Lesion Assay (“PLA”) available to its approximately 6 million members in the State of Texas.

Sundial Growers (NASDAQ: SNDL) 23.2% HIGHER; adds to Wednesday's intra-day gains of 79%.

Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) 20.2% HIGHER; today presented data from MARIO-275 (MAcrophage Reprogramming in Immune Oncology), a randomized, placebo-controlled Phase 2 study evaluating the efficacy and safety of eganelisib in combination with nivolumab (Opdivo®) in platinum-refractory, I/O naïve patients with advanced urothelial cancer (UC) during the 2021 ASCO Genitourinary Cancers Symposium (ASCO GU). The objective of MARIO-275 was to address the need for better treatments for second line (2L) advanced UC patients.

RealNetworks (NASDAQ: RNWK) 19.9% HIGHER; reported Q4 EPS of $0.16, versus ($0.08) reported last year. Revenue for the quarter came in at $17.6 million, versus $16.6 million reported last year.

Sonos (NASDAQ: SONO) 16.4% HIGHER; reported Q1 EPS of $1.17, $0.29 better than the analyst estimate of $0.88. Revenue for the quarter came in at $645.6 million versus the consensus estimate of $589.86 million. Sonos sees FY2021 revenue of $1.525-1.575 billion, versus the consensus of $1.46 billion.

Fluidigm (NASDAQ: FLDM) 16.3% LOWER; reported Q4 EPS of ($0.13), $0.06 worse than the analyst estimate of ($0.07). Revenue for the quarter came in at $44 million versus the consensus estimate of $50.72 million.

Mesoblast Limited (Nasdaq: MESO) 15% HIGHER; announced results from the Phase 3 randomized controlled trial of its allogeneic mesenchymal precursor cell (MPC) therapy rexlemestrocel-L in 404 enrolled patients with chronic low back pain (CLBP) due to degenerative disc disease (DDD) refractory to conventional treatments. The results indicate that a single injection of rexlemestrocel-L may provide a safe, durable, and effective opioid-sparing therapy for patients with chronic inflammatory back pain due to degenerative disc disease, and that greatest benefits are seen when administered earlier in the disease process before irreversible fibrosis of the intervertebral disc has occurred.

Callaway Golf (NYSE: ELY) 13% LOWER; reported Q4 EPS of ($0.33), $0.14 worse than the analyst estimate of ($0.19). Revenue for the quarter came in at $375 million versus the consensus estimate of $337.44 million.

Tilray, Inc. (NASDAQ: TLRY) 12% LOWER; falls after Wednesday's intra-day gains of 51%

Zillow (NASDAQ: Z) (NASDAQ: ZG) 11.8% HIGHER; reported Q4 revenue of $789 million versus the consensus estimate of $740.24 million. Entered into a definitive agreement to acquire ShowingTime.com, Inc., an online scheduling platform for home showings, for $500 million.

Kadmon Holdings, Inc. (NASDAQ: KDMN) 9.5% LOWER; today announced its intent to offer, subject to market conditions and other factors, $150 million aggregate principal amount of convertible senior notes due 2027 (the "Notes") in a private offering to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended. Kadmon also expects to grant the initial purchaser of the Notes a 13-day option to purchase up to an additional $30 million aggregate principal amount of the Notes, solely to cover over-allotments.

iRobot Corp. (NASDAQ: IRBT) 8.6% HIGHER; reported Q4 EPS of $0.84, $0.53 better than the analyst estimate of $0.31. Revenue for the quarter came in at $544.8 million versus the consensus estimate of $494.07 million. iRobot Corp. sees FY2021 EPS of $3.00-$3.25, versus the consensus of $2.19. iRobot Corp. sees FY2021 revenue of $1.635-1.675 billion, versus the consensus of $1.47 billion.

Onconova Therapeutics, Inc. (NASDAQ: ONTX) 6% LOWER; announced that it intends to offer and sell shares of its common stock in an underwritten public offering. All of the shares to be sold in the offering will be offered by Onconova. The offering is subject to market conditions and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. In addition, Onconova intends to grant the underwriters a thirty-day option to purchase up to an additional 15 percent of shares of its common stock offered in the public offering.

NANO-X IMAGING LTD (NASDAQ: NNOX) 5.4% LOWER; priced the previously announced underwritten public offering of 3,091,635 of its ordinary shares by certain non-officer, non-director shareholders at a public offering price of $62.50 per share. The offering is expected to close on or about February 16, 2021, subject to satisfaction of customary closing conditions.

Zynga (NASDAQ: ZNGA) 4.6% HIGHER; reported Q4 EPS of ($0.05), $0.14 worse than the analyst estimate of $0.09. Revenue for the quarter came in at $616 million versus the consensus estimate of $677.73 million.

TherapeuticsMD, Inc. (NASDAQ: TXMD) 4.2% LOWER; announced an underwritten public offering of its common stock. The Company has granted the underwriter a 30-day option to purchase up to an additional 15% of the number of shares of its common stock offered in the offering. All of the shares in the offering are to be sold by TherapeuticsMD.

You May Also Be Interested In

• Midday movers: Tesla, Li Auto and CNH Industrial fall; Salesforce rises
• United Homes Group (UHG) Announces Board Changes
• Infinite Reality Acquires the Drone Racing League for $250 Million, Solidifying Position as Global Leader in Immersive Technology & Experiences (NBST)